secwatch.observer — SEC 8-K summary
======================================

Issuer:     TransMedics Group, Inc. (TMDX)
CIK:        0001756262
Form:       8-K
Filed at:   2024-02-26T23:59:59+00:00
Accession:  0000950170-24-020175
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransMedics Q4 revenue $81.2M (+159% YoY); guides FY2024 $360-370M
------------------------------------------------------------------

- Q4 2023 revenue $81.2M (+159% YoY); net income $4.0M ($0.12 EPS) vs loss of $6.7M in Q4 2022.
- Full-year 2023 revenue $241.6M (+159% YoY); net loss narrowed to $25.0M from $36.2M.
- Gross margin declined to 59% (Q4) and 64% (FY) from 66% and 70% respectively.
- Cash position $394.8M as of Dec 31, 2023.
- FY2024 revenue guidance $360-370M, representing 49%-53% growth over 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1756262/000095017024020175/0000950170-24-020175-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1756262/000095017024020175/tmdx-20240226.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-020175

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer